瞬时受体电位香草酸亚型6（TRPV6）在预测食管鳞状细胞癌患者的生存率方面发挥着新作用。
TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma.
作者信息
Zhang Shui-Shen, Xie Xuan, Wen Jing, Luo Kong-Jia, Liu Qian-Wen, Yang Hong, Hu Yi, Fu Jian-Hua
机构信息
State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
Guangdong Esophageal Cancer Research Institute, Guangzhou, People's Republic of China.
出版信息
Diagn Pathol. 2016 Jan 27;11:14. doi: 10.1186/s13000-016-0457-7.
BACKGROUND
TRPV6 is over-expressed and promotes the proliferation and invasion in many cancers. The association between the expression of TRPV6 and clinical outcome in esophageal squamous cell carcinoma (ESCC) has not been studied yet. We aim to elucidate the role of TRPV6 in predicting prognosis of patients with ESCC.
METHODS
In the retrospective study, mRNA level of TRPV6 was examined in patients (N = 174) from Sun Yat-sen University Cancer Center (mRNA cohort) and protein level of TRPV6 was examined in patients (N = 218) from Linzhou Cancer Hospital (protein cohort). Statistical analysis was performed to test the clinical and prognostic significance of TRPV6.
RESULTS
TRPV6 was down-regulated in ESCC tissues and cell lines. Patients with downregulation of TRPV6 trended to have a higher rate of advanced pT stage in both mRNA cohort (P = 0.089) and protein cohort (P = 0.073), though not statistically significant. No significant association was observed between TRPV6 expression and disease-specific survival (DSS) in both two cohorts. However, stratified survival analysis based on the gender showed that in mRNA cohort, downregulation of TRPV6 was associated with an unfavorable 3-year DSS in patients with male (47.3 % vs 63.6 %, P = 0.027) and with favorable 3-year DSS in patients with female (66.7 % vs 43.0 %, P = 0.031). The result was confirmed in protein cohort. Male patients with downregulation of TRPV6 had a poor 3-year DSS (20.0 % vs 57.1 %,P < 0.001) while female counterparts showed an enhanced 3-year DSS (56.1 % vs 28.6 %, P = 0.005).
CONCLUSION
TRPV6 is down-regulated in ESCC. As a predictive biomarker, TRPV6 plays a Janus-like role in predicting survival of male and female ESCC patients.
背景
TRPV6在许多癌症中过度表达并促进细胞增殖和侵袭。目前尚未研究TRPV6的表达与食管鳞状细胞癌（ESCC）临床结局之间的关联。我们旨在阐明TRPV6在预测ESCC患者预后中的作用。
方法
在这项回顾性研究中，检测了中山大学肿瘤防治中心患者（N = 174）的TRPV6 mRNA水平（mRNA队列），并检测了林州肿瘤医院患者（N = 218）的TRPV6蛋白水平（蛋白队列）。进行统计分析以检验TRPV6的临床和预后意义。
结果
TRPV6在ESCC组织和细胞系中表达下调。在mRNA队列（P = 0.089）和蛋白队列（P = 0.073）中，TRPV6表达下调的患者均有晚期pT分期比例较高的趋势，尽管无统计学意义。在两个队列中均未观察到TRPV6表达与疾病特异性生存（DSS）之间存在显著关联。然而，基于性别的分层生存分析显示，在mRNA队列中，TRPV6表达下调与男性患者不良的3年DSS相关（47.3%对63.6%，P = 0.027），而与女性患者良好的3年DSS相关（66.7%对43.0%，P = 0.031）。该结果在蛋白队列中得到证实。TRPV6表达下调的男性患者3年DSS较差（20.0%对57.1%，P < 0.001），而女性患者3年DSS有所提高（56.1%对28.6%，P = 0.005）。
结论
TRPV6在ESCC中表达下调。作为一种预测生物标志物，TRPV6在预测男性和女性ESCC患者生存方面发挥着两面性的作用。
Zotero 插件